EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current clinical application of incretin therapy for obesity management

Karlie Skinner, Jennifer N Clements iD

Canadian Journal of Physiology and Pharmacology · 2026

DOI: 10.1139/cjpp-2025-0152 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Karlie Skinner und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of South Carolina College of Pharmacy, 715 Sumter Street, Columbia, SC 29208, USA. Hauptthemen laut MEDLINE: Incretins, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incretin therapy, utilizing glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonists, is a cornerstone of obesity management due to effects on appetite suppression, weight loss, and metabolic improvement. Liraglutide, semaglutide, and tirzepatide promote weight reduction by modulating incretin hormone pathways, leading to decreased caloric intake. Recent studies with semaglutide and tirzepatide have demonstrated substantial weight loss outcomes beyond glucose-lowering benefits, shifting the paradigm of obesity treatment toward pharmacological interventions. While effective in weight loss, challenges remain regarding long-term efficacy, tolerability, and accessibility. Future directions include optimizing combination therapies and exploring novel incretin-based molecules with dual or triple receptor activity. This review focuses on the clinical application of incretin therapy in obesity, emphasizing practical considerations and highlighting therapeutic benefits for obesity to improve outcomes and public health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsObesityAnti-Obesity AgentsHumansAnimalsGlucagon-Like Peptide-1 Receptor AgonistsWeight LossLiraglutideGlucagon-Like Peptides

Stichwörter der Autor:innen

GIPGLP-1incretinobesitypharmacotherapy

Substanzen

IncretinsGlucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsLiraglutideGlucagon-Like Peptides

Autor:innen und Institutionen

  • University of South Carolina College of Pharmacy, 715 Sumter Street, Columbia, SC 29208, USA.
  • University of South Carolina College of Pharmacy, 607 Grove Road, Greenville, SC 29605, USA.

ORCID-Profile: Jennifer N Clements

Zitieren

APA

Skinner, K., & Clements, J. (2026). Current clinical application of incretin therapy for obesity management. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0152

Vancouver

Skinner K, Clements J. Current clinical application of incretin therapy for obesity management. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0152

BibTeX
@article{Skinner2026,
  author = {Skinner, Karlie and Clements, Jennifer N},
  title = {Current clinical application of incretin therapy for obesity management},
  journal = {Canadian Journal of Physiology and Pharmacology},
  year = {2026},
  doi = {10.1139/cjpp-2025-0152}
}
Kostenlos starten →